58
BIBLIOGRAFIA
1. Shorter E. From paralysis to fatigue: a history of psychosomatic illness in the modern era. New York: NY FreePress, 1992.
2. Wessely S. Old wine in new bottles: neurasthenia and ‘ME’.
Psychol Med 1990; 20: 35–53.
3. Tratto dal sito internet medico e bambino.
4. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic
fatiguesyndrome: a working case definition. Ann Intern Med 1988; 108:378–79.
5. Sharpe MC, Archard LC, Banatvala JE, et al. A report—chronic fatigue syndrome: guidelines for research. J R Soc Med 1991;
84:118–21.
6. Lloyd AR, Hickie I, Boughton CR, Spencer O, Wakefield D.Prevalence of chronic fatigue syndrome in an
Australianpopulation. Med J Aust 1990; 153: 522–28.
7. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study.Ann Intern Med 1994; 121: 953 59.
8. Tratto dal sito internet medico e bambino.
9. Reyes M, Nisenbaum R, Hoaglin DC, et al. Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. Arch Intern Med 2003; 163: 15.
10. Jason LA, Richman JA, Rademaker AW, et al. A community- based study of chronic fatigue syndrome. Arch Intern Med 1999; 159: 2129–37.
11. Wessely S, Chalder T, Hirsch S, Wallace P, Wright D. The prevalence and morbidity of chronic fatigue and chronic fatigue
59
syndrome: a prospective primary care study. Am J Public Health 1997; 87: 1449–55.
12. Jordan KM, Landis DA, Downey MC, Osterman SL, Thurm AE, Jason LA. Chronic fatigue syndrome in children and adolescents: a review. J Adolesc Health 1998; 22: 4–18.
13. Chalder T, Goodman R, Wessely S, Hotopf M, Meltzer H.
Epidemiology of chronic fatigue syndrome and self reported myalgic encephalomyelitis in 5–15 year olds: cross sectional study. BMJ 2003; 327: 654–55.
14. Jones J, Nisenbaum R, Solomon L, Reyes M, Reeves WC.
Chronic fatigue syndrome and other fatiguing illnesses in adolescents: a population based study. J Adolesc Health 2004;
35: 34–40.
15. Cairns R, Hotopf M. A systematic review describing the prognosis of chronic fatigue syndrome. Occup Med 2005; 55:
20–31.
16. Vercoulen JHMM, Swanink CMA, Fennis JFM, Galama JMD, van der Meer JWM, Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 1994; 38: 383–92.
17. Komaroff AL, Fagioli LR, Geiger AM, et al. An examination of the working case definition of chronic fatigue syndrome. Am J Med 1996; 100: 56–64.
18. Swanink CMA, van der Meer JWM, Vercoulen JHHM, et al.
Epstein-Barr virus (EBV) and the chronic fatigue syndrome:
normal virus load in blood and normal immunologic reactivity in the EBV regression assay. Clin Infect Dis 1995; 20: 1390–92.
19. Schluederberg A, Straus SE, Peterson P, et al. Chronic fatigue syndrome research: definition and medical outcome assessment.
Ann Intern Med 1992; 117: 325–31.
20. Salit IE. Precipitating factors for the chronic fatigue syndrome.
J Psychiatr Res 1997; 31: 59–65.
60
21. Solomon L, Nisenbaum R, Reyes M, Papanicolaou DA, Reeves WC. Functional status of persons with chronic fatigue
syndrome in the Wichita, Kansas, population. Health Qual Life Outcomes 2003; 1: 48.
22. Wessely S, Hotopf M, Sharpe M. Chronic fatigue and its syndromes. Oxford: Oxford University Press, 1998.
23. Cleare AJ. The neuroendocrinology of chronic fatigue syndrome. Endocr Rev 2003; 24: 236–52.
24. (Kerr JR, Petty R, Burke B, Gough J, Fear D, Sinclair LI, Mattey DL, Richards SC, Montgomery J, Baldwin DA, Kellam P, Harrison TJ, Griffin GE, Main J, Enlander D, Nutt DJ,
Holgate ST: Gene expression subtypes in patients with chronic fatigue syndrome/myalgic ncephalomyelitis. J Infect Dis 2008, 197:1171–1184.
25. Gow JW, Hagan S, Herzyk P, Cannon C, Behan PO, Chaudhuri A: A gene signature for post-infectious chronic fatigue
syndrome. BMC Med Genomics 2009, 2:38.
26. Vernon SD, Unger ER, Dimulescu IM, Rajeevan M, Reeves WC: Utility of the blood for gene expression profiling and biomarker discovery in chronic fatigue syndrome. Dis Markers 2002, 18:193–199.).
27. (Nancy AL, Shoenfeld Y: Chronic fatigue syndrome with autoantibodies–the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev 2008, 8:52–55.
28. Rosenblum H, Shoenfeld Y, Amital H: The common immunogenic etiology of chronic fatigue syndrome: from infections to vaccinesvia adjuvants to the ASIA syndrome.
Infect Dis Clin North Am 2011, 25:851–863.).
29. Hoogveld S, Prins J, de Jong L, et al.
Persoonlijkheidskenmerken en het chronisch
vermoeidheidssyndroom: een literatuuroverzicht (Personality
61
characteristics and the chronic fatigue syndrome: a review of the literature). Gedragstherapie 2001; 34: 275–305.
30. White PD. What causes chronic fatigue syndrome? BMJ 2004;
329: 928–29.
31.Viner R, Hotopf M. Childhood predictors of self reported chronic fatigue syndrome/myalgic encephalomyelitis in adults:
national birth cohort study. BMJ 2004; 329: 941.
32. Hickie I, Kirk K, Martin N. Unique genetic and environmental determinants of prolonged fatigue: a twin study. Psychol Med 1999; 29: 259–68.
33. Hickie I, Bennett B, Lloyd A, Heath A, Martin N. Complex genetic and environmental relationships between psychological distress, fatigue and immune functioning: a twin study. Psychol Med 1999; 29: 269–77.
34. Buchwald D, Herrell R, Ashton S, Belcourt M, Schmaling K, Goldberg J. A twin study of chronic fatigue. Psychosom Med 2001; 63: 936–43.
35. De Becker P, McGregor N, de Meirleir K. Possible triggers and mode of onset of chronic fatigue syndrome. J Chronic Fatigue Syndr 2002; 10: 3–18.
36. Afari N, Buchwald D. Chronic fatigue syndrome: a review.
AmJ Psychiatry 2003; 160: 221–36.
37. Buchwald DS, Rea TD, Katon WJ, et al. Acute infectious mononucleosis: characteristics of patients who report failure to recover. Am J Med 2000; 109: 531–37.
38. Lloyd AR. Postinfective fatigue. In: Jason LA, Fennell PA, Taylor RR, eds. Handbook of chronic fatigue syndrome.
Hoboken, New Jersey: John Wiley & Sons 2003: 108–23.
39. White PD, Thomas JM, Kangro HO, et al. Predictions and associations of fatigue syndromes and mood disorders that
62
occur after infectious mononucleosis. Lancet 2001; 358: 1946–
54.
40. Hatcher S, House A. Life events, difficulties and dilemmas in the onset of chronic fatigue syndrome: a case-control study.
Psychol Med 2003; 33: 1185–92.
41. Theorell T, Blomkvist V, Lindh G, Evengard B. Critical life events, infections, and symptoms during the year preceding chronic fatigue syndrome (CFS): an examination of CFS patients and subjects with a nonspecific life crisis. Psychosom Med 1999; 61:304–10.
42. Vercoulen JHMM, Swanink CMA, Galama JMD, et al. The persistence of fatigue in chronic fatigue syndrome and multiple sclerosis: the development of a model. J Psychosom Res 1998;
45:507–17.
43. Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue and chronic fatigue syndrome: a systematic review. QJM 1997;
90:223–33.
44. Heijmans JWM. Coping and adaptive outcome in chronic fatigue syndrome: importance of illness cognitions. J Psychosom Res 1998;45: 39–51.
45. Moss-Morris R, Petrie KJ, Weinman J. Functioning in chronic fatigue syndrome: do illness perceptions play a regulatory role?Br J Health Psychol 1996; 1: 15–25.
46. Schmaling KB, Smith WR, Buchwald DS. Significant other responses are associated with fatigue and functional status among patients with chronic fatigue syndrome. Psychosom Med2000; 62: 444–50.
47. Prins JB, Bos L, Servaes P, et al. Social support and thepersistence of complaints in chronic fatigue syndrome.Psychother Psychosom 2004; 73: 174–82.
63
48. Stanley I, Salmon P, Peters S. Doctors and social epidemics: the problem of persistent unexplained physical symptoms,
including chronic fatigue. Br J Gen Pract 2002; 52: 355–56.
49. Page LA, Wessely S. Medically unexplained symptoms:
exacerbating factors in the doctor-patient encounter. J R Soc Med2003; 96: 223–27.
50. Lyall M, Peakman M, Wessely S. A systematic review and critical evaluation of the immunology of chronic fatigue syndrome.J Psychosom Res 2003; 55: 79–90.
51. Kelley Kw, Bluthe RM, Dantzer R, et al. Cytokine-
inducedsickness behavior. Brain Behav Immun 2003; 17: S112–
18.
52. Konsman JP, Parnet P, Dantzer R. Cytokine-induced sicknessbehaviour: mechanisms and implications. Trends Neurosci 2002;25: 154–59.
53. Vollmer CU. Acute sickness behaviour: an immune system- tobraincommunication? Psychol Med 2001; 31: 761–67.
54. Capuron L, Gumnick JF, Musselman DL, et al.
Neurobehavioraleffects of interferon-alpha in cancer patients:
phenomenology and paroxetine responsiveness of symptom dimensions.Neuropsychopharmacology 2002; 26: 643–.
55. Tratto dal sito internet sindrome da fatica cronica contenuto in medicina generale.
56. Tratto dall’ articolo Chronic fatigue syndrome and mitochondrial dysfunction.
57. Tratto dal sito internet sindrome da fatica cronica contenuto in medicina generale.
58. Murphy, M. P. (2009).How mitochondria produce reactiveoxygen species. Biochem. J. 417, 1-13.
64
59. Mitochondrial diseases in man and mouse. Wallace, D.C(1999) Science 238 (5407) 1482-1488.
60. David L. Nelson, Michael M. Cox, I Principi di Biochimica di Lehninger, 3° ed., Bologna, Zanichelli, febbraio 2002.
61. The permeability transition pore complex : another wiew.
Halestrap AP, McStay GP,Clarke SJ, 2002.
62. Behan WMH, More IAR and Behan PO. Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathol (Berl)1991;83:61-65.
63. Byrne E, Trounce I and Dennett X.Chronic relapsing
myalgiaclinical, histological and biochemical studies. Aust NZJ med 1985;15:305-308
64. Vecchiet L,Montanari G, Pizzigallo E, lezzi S, de Bigontina P, Dragani L, Vecchiet Jand Giamberardino MA Sensory
characterization of somatic parietal tissues in humans with chronic fatigue syndrome . Neurosci Lett 1996; 208: 117-120.
65. Zhang C, Baumer A, Mackay IR, Linnane AW and Nagley P.
Unusual pattern of mitochondrial DNA deletions in skeletal muscle of an adult human with chronic fatigue syndrome. Hum Mol Genet 1995; 4: 751-754.
66. Kuratsune H, Yamaguti K, Takahashi M, Misaki H, Tagawa S and Kitani T. Acylcarnitine deficiency in chronic fatigue syndrome. Clin Infect Dis 1994; 18: S62-S67.
67. Plioplys AV and Plioplys S. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates.
Neuropsychobiology 1995; 32: 132-138.
68. Anderson NG, Anderson NL.Twenty years of two-dimensional electrophoresis: past, present and future. Electrophoresis1996;
17: 443- 444.
69. Wasinger VC, Cordwell SJ, Cerpa-Poljak A, Yan JX,
GooleyAA, Wilkins MR, Duncan MW, Harris R, Williams KL,
65
andHumphery- Smith I.Progress with gene-product mapping oftheMollicutes:Mycoplasmagenitalium.Electrophoresis1995;1 6:1090-1094.
70. Wilkins MR, Sanchez JC, Gooley AA, Appel RD, Humphery- Smith I, Hochstrasser DF, and Williams KL. Progress
withproteome projects: why all proteins expressed by a genomeshould be identified and how to do it. Biotechnol.
Genet. Eng.Rev 1995; 13: 19-50.
71. Graves PR, Haystead TAJ.Molecoular biologist’s guide to proteomics. Microbiol Mol Biol Rev 2002; 66: 39-46.
72. Hoog CL, Mann M. Proteomics. Annu Rev Genomics HumGenet 2004; 5: 267-293.
73. Stults JT, Arnott D. Proteomics. Methods in enzymology 2005;(402): 245-278.
74. Godovac-Zimmermann J, Soskic V, Poznanovic S, Brianza F.Functional proteomics of signal transduction by
membranereceptors. Electrophoresis 1999; 20 (4-5): 952-961.
75. Imam-Sghiouar N, Laude-Lemaire I, Labas V, Pflieger D, LeCaer JP, Caron M, Nabias DK, Joubert-Caron
R.Subproteomicsanalysis of phosphorylated proteins:
application to thestudy of B-lymphoblast from a patient with Scott syndrome.Proteomics 2002; 2 (7): 828-838.
76. Choudhary J, Grant SGN. Proteomics in postgenomic
neuroscience:the end of the beginning. Nature Neuroscience 2004;5 (7): 440-445.
77. Phizicky E, Bastiaens PI, Zhu H, Snyder M, Fields
S.Proteinanalysis on a proteomic scale. Nature 2003; 422: 208- 215.
78. Pandey A, Mann M. Proteomics to study genes and genomes.Nature 2000; 405: 837-846.
66
79. Herbert BR et al.What place for polyacrylamide in proteomics?.Trends Biotechnol 2001; 19: S3-S9.
80. Identification of Novel MAP Kinase Pathway Signaling Targetsby Functional Proteomics and Mass Spectrometry.
TimothyS. Lewis, John B. Hunts, Lauren D. Aveline, Karen R.
Jonscher,Donna F. Louie, Jennifer M. Yeh, Theresa S.
Nahreini,Katheryn A. Resing, Natalie G. Ahn. (2000).
Molecular Cell 6,1343-1354.
81. Lodish H, Berk A, S. Lawerence Zipursky, Matsudaira P,Baltimore D, Darnell J E.Biologia molecolare della cellula.Zanichelli, seconda edizione 2002; 3: 97-106.
82. Molloy M. P.Two-dimensional electrophoresis of membraneprotein using immobilized pH gradients.
AnalyticalBiochemistry (2000); 280 (1): 1-10.
83. Sanchez JC, Rouge V, Pisteur M, Ravier F, Tonella L, MoosmayerM, Wilkins MR, Hochstrasser DF.Improved and simplifiedin-gel sample application using reswelling of dryimmobilized pH gradients. Electrophoresis 1997; 18:324- 327.
84. Peterson GL. “Review of the Folin phenol protein quantitation method of Lowry, Rosebrough, Farr and Randall”. Anal
Bioche1979; 100: 201-20.
85. An introduction to practical biotechnology by S. Harisha,Laxmi Publications, 2006.
86. Modern Experimental Biochemistry,third edition . RobertBoyer, 2007, Dorling Kindersley (India) Pvt. Ltd.
87. (Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med.
2009; 2: 1.
88. Booth NE, Myhill S, McLaren-Howard J. Mitochondrial dysfunction and the pathophysiology of Myalgic
67
Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Int J Clin Exp Med. 2012; 5: 208-220.).
89. (Morris G, Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metab Brain Dis. 2014;29: 19-36).
